



NATIONAL MEDICAL SERVICES

November 25, 2005

Dear Valued Client:

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled the enclosed packet of important changes regarding a number of tests we perform. Listed below are the types of changes included in this packet.

Category	Type of Change
I.	Tests that have had changes to their method/CPT code, units of measurement, scope of analysis or specimen requirements
II.	Tests that have been discontinued
III.	Tests that have had reference comment changes

Please be advised that the changes listed in this packet will go into effect on **March 1, 2006**. Please use this packet of information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

We apologize if this causes you any inconvenience. If you have any questions about the information contained in this packet, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of National Medical Services and your assistance in implementing these changes.

Sincerely,

National Medical Services, Inc.

Database Changes - Summary

Categories:

- I: Method/CPT Code, Units, Scope of Analysis and Specimen Requirements
- II: Deleted tests
- III: Reference comment changes

Test Code	Test Name	Category		
		I	II	III
0457U	Aromatic Solvents Panel, Urine	•		
0460ST	Arsenic, Stool	•		
0512ST	Barbiturates Screen, Stool	•		
0921ST	Cadmium, Stool	•		
1330ST	Copper, Stool	•		
2029U	Ethylbenzene Exposure Biouptake, Urine	•		
2150B	Gallium, Blood			•
2150R	Gallium, RBCs			•
2150SP	Gallium, Serum/Plasma			•
2150U	Gallium, Urine	•		•
2416U	Inhalants Metabolites Panel, Urine	•		
2417U	Inhalants Intoxicants Survey, Urine	•		
2426U	Inhalants and Metabolites Panel, Urine	•		
2670ST	Mercury, Stool	•		
2850ST	Methaqualone Screen, Stool	•		
3000SP	Ethylene Glycol Monomethyl Ether, Serum/Plasma	•		
3127B	Naphthylamines, Blood		•	
3127SP	Naphthylamines, Serum/Plasma		•	
3127U	Naphthylamines, Urine		•	
3233B	GC Screen for Medical Professional Abuse, Blood (Forensic)			•
3233SP	GC Screen for Medical Professional Abuse, Serum/Plasma (Forensic)			•
3270B	Oxycodone - Free (Unconjugated), Blood	•		
3270FL	Oxycodone - Free (Unconjugated), Fluid	•		
3270SP	Oxycodone - Free (Unconjugated), Serum/Plasma	•		
3400B	Pentazocine, Blood			•
3400SP	Pentazocine, Serum/Plasma			•
3435B	Percocet, Blood	•		
3435FL	Percocet, Fluid	•		
3435SP	Percocet, Serum/Plasma	•		
3435TI	Percocet, Tissue	•		
3435U	Percocet, Urine	•		
3436B	Percodan, Blood	•		
3436SP	Percodan, Serum/Plasma	•		
4844ST	Zinc, Stool	•		
5509B	Doxepin and Metabolite Confirmation, Blood			•
5524B	Fluoxetine and Metabolite Confirmation, Blood			•
5524SP	Fluoxetine and Metabolite Confirmation, Serum/Plasma			•
5545SP	Phenothiazines Confirmation, Serum/Plasma			•
5613B	Lidocaine and Metabolite (MEGX) Confirmation, Blood			•
5613SP	Lidocaine and Metabolite (MEGX) Confirmation, Serum/Plasma			•
5618B	Pentazocine Confirmation, Blood			•
5618SP	Pentazocine Confirmation, Serum/Plasma			•
5790B	GC Confirmation for Medical Professional Abuse, Blood			•
5790SP	GC Confirmation for Medical Professional Abuse, Serum/Plasma			•
5791B	GC Confirmation for Medical Professional Abuse, Blood			•
5791SP	GC Confirmation for Medical Professional Abuse, Serum/Plasma			•

National Medical Services, Inc.

3701 Welsh Road, Willow Grove, PA 19090

800-522-6671

Database Changes - Summary

Categories:

- I: Method/CPT Code, Units, Scope of Analysis and Specimen Requirements
- II: Deleted tests
- III: Reference comment changes

Test Code	Test Name	Category		
		I	II	III
8663B	Hydrocodone and Metabolites - Free (Unconjugated), Blood	•		
8663FL	Hydrocodone and Metabolites - Free (Unconjugated), Fluid	•		
8663SP	Hydrocodone and Metabolites - Free (Unconjugated), Serum/Plasma	•		
8663TI	Hydrocodone and Metabolites - Total (Conjugated/Unconjugated), Tissue	•		
8663U	Hydrocodone and Metabolites - Total (Conjugated/Unconjugated), Urine	•		
8667B	Oxycodone and Metabolite - Free (Unconjugated), Blood	•		
8667FL	Oxycodone and Metabolite - Free (Unconjugated), Fluid	•		
8667SP	Oxycodone and Metabolite - Free (Unconjugated), Serum/Plasma	•		
8667TI	Oxycodone and Metabolite - Total (Conjugated/Unconjugated), Tissue	•		
8667U	Oxycodone and Metabolite - Total (Conjugated/Unconjugated), Urine	•		
8682B	Fluphenazine, Blood			•
8682SP	Fluphenazine, Serum/Plasma			•
8705B	Doxepin and Metabolite, Blood			•
8723B	Pentazocine, Blood			•
9179B	Fluoxetine and Metabolite Screen, Blood			•
9179SP	Fluoxetine and Metabolite Screen, Serum/Plasma			•
9317SP	Lidocaine and Metabolite (MEGX) Screen, Serum/Plasma			•
9356ST	Cannabinoids Screen, Stool	•		
9400B	Drugs of Abuse - Medical Professionals, Blood (Forensic)			•
9400SP	Drugs of Abuse - Medical Professionals, Serum/Plasma (Forensic)			•
9420SP	Phenothiazines Screen, Serum/Plasma			•
9435B	Doxepin and Metabolite Screen, Blood			•
9441B	Pentazocine Screen, Blood			•
9441SP	Pentazocine Screen, Serum/Plasma			•

National Medical Services, Inc.

3701 Welsh Road, Willow Grove, PA 19090

800-522-6671

Changes effective:
March 1, 2006

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

TEST CHANGES – CATEGORY I

Method/CPT Code, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Method/CPT Code	Units
0457U	Aromatic Solvents Panel, Urine Specimen Requirements: 20 mL Urine Notes: Collect sample at end of shift at end of work week. Freeze and ship frozen. Frozen requirement was added.		
0460ST	Arsenic, Stool Specimen Requirements: 2 g Stool Solid Notes: Freeze and ship frozen. Frozen requirement was added.		
0512ST	Barbiturates Screen, Stool Specimen Requirements: 2 g Stool Solid Notes: Freeze and ship frozen. Frozen requirement was added.		
0921ST	Cadmium, Stool Specimen Requirements: 2 g Stool Solid Notes: Freeze and ship frozen. Frozen requirement was added.		
9356ST	Cannabinoids Screen, Stool Specimen Requirements: 2 g Stool Solid Notes: Freeze and ship frozen. Frozen requirement was added.		
1330ST	Copper, Stool Specimen Requirements: 2 g Stool Solid Notes: Freeze and ship frozen. Frozen requirement was added.		
2029U	Ethylbenzene Exposure Biouptake, Urine <ul style="list-style-type: none"> • Creatinine • Mandelic Acid • Mandelic Acid (Creatinine corrected) Mandelic Acid (Creatinine correction) was removed. Mandelic Acid (Creatinine corrected) was added [g/g Creat; IC]. Order of reported analytes was changed.	Colorimetry (82570) IC (83921) IC	g/g Creat
3000SP	Ethylene Glycol Monomethyl Ether, Serum/Plasma <ul style="list-style-type: none"> • Ethylene Glycol Monomethyl Ether Methyl Cellosolve was removed. Ethylene Glycol Monomethyl Ether was added [mcg/mL; GC].	GC (84600)	mcg/mL
2150U	Gallium, Urine <ul style="list-style-type: none"> • Gallium Units were changed.	ICP/MS (83018)	mcg/L

Changes effective:
March 1, 2006

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

TEST CHANGES – CATEGORY I

Method/CPT Code, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Method/CPT Code	Units
8663B	Hydrocodone and Metabolites - Free (Unconjugated), Blood <ul style="list-style-type: none"> • Hydrocodone - Free • Hydromorphone - Free • Dihydrocodeine - Free Hydrocodone, Hydromorphone and Dihydrocodeine were removed. Hydrocodone - Free [ng/mL; GC/MS], Hydromorphone - Free [ng/mL; GC/MS] and Dihydrocodeine - Free [ng/mL; GC/MS] were added. Test Name was changed.	GC/MS (83925) GC/MS GC/MS	ng/mL ng/mL ng/mL
8663FL	Hydrocodone and Metabolites - Free (Unconjugated), Fluid <ul style="list-style-type: none"> • Hydrocodone - Free • Hydromorphone - Free • Dihydrocodeine - Free Hydrocodone, Hydromorphone and Dihydrocodeine were removed. Hydrocodone - Free [ng/mL; GC/MS], Hydromorphone - Free [ng/mL; GC/MS] and Dihydrocodeine - Free [ng/mL; GC/MS] were added. Test Name was changed.	GC/MS (83925) GC/MS GC/MS	ng/mL ng/mL ng/mL
8663SP	Hydrocodone and Metabolites - Free (Unconjugated), Serum/Plasma <ul style="list-style-type: none"> • Hydrocodone - Free • Hydromorphone - Free • Dihydrocodeine - Free Hydrocodone, Hydromorphone and Dihydrocodeine were removed. Hydrocodone - Free [ng/mL; GC/MS], Hydromorphone - Free [ng/mL; GC/MS] and Dihydrocodeine - Free [ng/mL; GC/MS] were added. Test Name was changed.	GC/MS (83925) GC/MS GC/MS	ng/mL ng/mL ng/mL
8663TI	Hydrocodone and Metabolites - Total (Unconjugated), Tissue <ul style="list-style-type: none"> • Hydrocodone - Total • Hydromorphone - Total • Dihydrocodeine - Total Hydrocodone, Hydromorphone and Dihydrocodeine were removed. Hydrocodone - Total [ng/g; GC/MS], Hydromorphone - Total [ng/g; GC/MS] and Dihydrocodeine - Total [ng/g; GC/MS] were added. Test Name was changed.	GC/MS (83925) GC/MS GC/MS	ng/g ng/g ng/g
8663U	Hydrocodone and Metabolites - Total (Conjugated/Unconjugated), Urine <ul style="list-style-type: none"> • Hydrocodone - Total • Hydromorphone - Total • Dihydrocodeine - Total Hydrocodone, Hydromorphone and Dihydrocodeine were removed. Hydrocodone - Total [ng/mL; GC/MS], Hydromorphone - Total [ng/mL; GC/MS] and Dihydrocodeine - Total [ng/mL; GC/MS] were added. Test Name was changed.	GC/MS (83925) GC/MS GC/MS	ng/mL ng/mL ng/mL

Changes effective:
March 1, 2006

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

TEST CHANGES – CATEGORY I

Method/CPT Code, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Method/CPT Code	Units
2426U	Inhalants and Metabolites Panel, Urine		
	• Phenol - Total	GC (84600)	mg/L
	• o-Cresol	GC	mg/L
	• Acetone	GC (84600)	mg/dL
	• Ethanol	GC	mg/dL
	• Isopropanol	GC	mg/dL
	• Methanol	GC	mg/dL
	• Methyl Ethyl Ketone	GC	mcg/mL
	• Methyl Isobutyl Ketone	GC	mcg/mL
	• Hippuric Acid	IC (83921)	g/L
	• Methylhippuric Acid	IC	g/L
	• Mandelic Acid	IC	g/L
	• Phenylglyoxylic Acid	IC	g/L
	• Trichloro-organic Metabolites	SP (83921)	mg/L
	Trichlororganic Metabolites was removed.		
	Trichloro-organic Metabolites was added [mg/L; SP].		
2417U	Inhalants Intoxicants Survey, Urine		
	• Phenol - Total	GC (84600)	mg/L
	• o-Cresol	GC	mg/L
	• Hippuric Acid	IC (83921)	g/L
	• Methylhippuric Acid	IC	g/L
	• Trichloro-organic Metabolites	SP (83921)	mg/L
	Trichlororganic Metabolites was removed.		
	Trichloro-organic Metabolites was added [mg/L; SP].		
2416U	Inhalants Metabolites Panel, Urine		
	• Phenol - Total	GC	mg/L
	• o-Cresol	GC	mg/L
	• Hippuric Acid	IC (83921)	g/L
	• Methylhippuric Acid	IC	g/L
	• Mandelic Acid	IC	g/L
	• Phenylglyoxylic Acid	IC	g/L
	• Trichloro-organic Metabolites	SP (83921)	mg/L
	Trichlororganic Metabolites was removed.		
	Trichloro-organic Metabolites was added [mg/L; SP].		
2670ST	Mercury, Stool		
	Specimen Requirements: 2 g Stool Solid		
	Notes: Freeze and ship frozen.		
	Frozen requirement was added.		
2850ST	Methaqualone Screen, Stool		
	Specimen Requirements: 2 g Stool Solid		
	Notes: Freeze and ship frozen.		
	Frozen requirement was added.		

Changes effective:
March 1, 2006

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

TEST CHANGES – CATEGORY I

Method/CPT Code, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Method/CPT Code	Units
3270B	Oxycodone - Free (Unconjugated), Blood • Oxycodone - Free Oxycodone was removed. Oxycodone - Free was added [ng/mL; GC/MS]. Test Name was changed.	GC/MS (83925)	ng/mL
3270FL	Oxycodone - Free (Unconjugated), Fluid • Oxycodone - Free Oxycodone was removed. Oxycodone - Free was added. Test Name was changed.	GC/MS (83925)	ng/mL
3270SP	Oxycodone - Free (Unconjugated), Serum/Plasma • Oxycodone - Free Oxycodone was removed. Oxycodone - Free was added [ng/mL; GC/MS]. Test Name was changed.	GC/MS (83925)	ng/mL
8667B	Oxycodone and Metabolite - Free (Unconjugated), Blood • Oxycodone - Free • Oxymorphone - Free Oxycodone and Oxymorphone were removed. Oxycodone - Free [ng/mL; GC/MS] and Oxymorphone - Free [ng/mL; GC/MS] were added. Test Name was changed.	GC/MS (83925) GC/MS	ng/mL ng/mL
8667FL	Oxycodone and Metabolite - Free (Unconjugated), Fluid • Oxycodone - Free • Oxymorphone - Free Oxycodone and Oxymorphone were removed. Oxycodone - Free [ng/mL; GC/MS] and Oxymorphone - Free [ng/mL; GC/MS] were added. Test Name was changed.	GC/MS (83925) GC/MS	ng/mL ng/mL
8667SP	Oxycodone and Metabolite - Free (Unconjugated), Serum/Plasma • Oxycodone - Free • Oxymorphone - Free Oxycodone and Oxymorphone were removed. Oxycodone - Free [ng/mL; GC/MS] and Oxymorphone - Free [ng/mL; GC/MS] were added. Test Name was changed.	GC/MS (83925) GC/MS	ng/mL ng/mL
8667TI	Oxycodone and Metabolite - Total (Conjugated/Unconjugated), Tissue • Oxycodone - Total • Oxymorphone - Total Oxycodone and Oxymorphone were removed. Oxycodone - Total [ng/g; GC/MS] and Oxymorphone - Total [ng/g; GC/MS] were added. Test Name was changed.	GC/MS (83925) GC/MS	ng/g ng/g
8667U	Oxycodone and Metabolite - Total (Conjugated/Unconjugated), Urine • Oxycodone - Total • Oxymorphone - Total Oxycodone and Oxymorphone were removed. Oxycodone - Total [ng/mL; GC/MS] and Oxymorphone - Total [ng/mL; GC/MS] were added. Test Name was changed.	GC/MS (83925) GC/MS	ng/mL ng/mL

Changes effective:
March 1, 2006

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

TEST CHANGES – CATEGORY I

Method/CPT Code, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name	Method/CPT Code	Units
3435B	Percocet, Blood <ul style="list-style-type: none"> • Acetaminophen • Oxycodone - Free Oxycodone was removed. Oxycodone - Free was added [ng/mL; GC/MS].	HPLC (82003) GC/MS (83925)	mcg/mL ng/mL
3435FL	Percocet, Fluid <ul style="list-style-type: none"> • Acetaminophen • Oxycodone - Free Oxycodone was removed. Oxycodone - Free was added [ng/mL; GC/MS].	HPLC (82003) GC/MS (83925)	mcg/mL ng/mL
3435SP	Percocet, Serum/Plasma <ul style="list-style-type: none"> • Acetaminophen • Oxycodone - Free Oxycodone was removed. Oxycodone - Free was added [ng/mL; GC/MS].	HPLC (82003) GC/MS (83925)	mcg/mL ng/mL
3435TI	Percocet, Tissue <ul style="list-style-type: none"> • Acetaminophen • Oxycodone - Total Oxycodone was removed. Oxycodone - Total was added [ng/g; GC/MS].	HPLC (82003) GC/MS (83925)	mcg/g ng/g
3435U	Percocet, Urine <ul style="list-style-type: none"> • Acetaminophen • Oxycodone - Total • Oxymorphone - Total Oxycodone and Oxymorphone were removed. Oxycodone - Total [ng/mL; GC/MS] and Oxymorphone - Total [ng/mL; GC/MS] were added.	HPLC (82003) GC/MS (83925) GC/MS	mcg/mL ng/mL ng/mL
3436B	Percodan, Blood <ul style="list-style-type: none"> • Salicylates • Oxycodone - Free Oxycodone was removed. Oxycodone - Free [ng/mL; GC/MS] was added.	SP (80196) GC/MS (83925)	mcg/mL ng/mL
3436SP	Percodan, Serum/Plasma <ul style="list-style-type: none"> • Salicylates • Oxycodone - Free Oxycodone was removed. Oxycodone - Free [ng/mL; GC/MS] was added.	SP (80196) GC/MS (83925)	mcg/mL ng/mL
4844ST	Zinc, Stool Specimen Requirements: 2 g Stool Solid Notes: Freeze and ship frozen. Frozen requirement was added.		

Changes effective:
March 1, 2006

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

DISCONTINUED TESTS – CATEGORY II

Test Code	Test Name	Alternative Test
3127B	Naphthylamines, Blood	No alternate test available.
3127SP	Naphthylamines, Serum/Plasma	No alternate test available.
3127U	Naphthylamines, Urine	No alternate test available.

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
8705B	Doxepin and Metabolite, Blood <ul style="list-style-type: none"> Doxepin Desmethyldoxepin 	<p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 5 - 115 ng Doxepin/mL.</p> <p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 0 - 80 ng Desmethyldoxepin/mL.</p>
9435B	Doxepin and Metabolite Screen, Blood <ul style="list-style-type: none"> Doxepin Desmethyldoxepin 	<p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 5 - 115 ng Doxepin/mL.</p> <p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 0 - 80 ng Desmethyldoxepin/mL.</p>
5509B	Doxepin and Metabolite Confirmation, Blood <ul style="list-style-type: none"> Doxepin Desmethyldoxepin 	<p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 5 - 115 ng Doxepin/mL.</p> <p>Patients on an average antidepressant dose of 113 mg Doxepin/day: 0 - 80 ng Desmethyldoxepin/mL.</p>
9400B	Drugs of Abuse - Medical Professionals, Blood (Forensic) <ul style="list-style-type: none"> Pentazocine 	<p>Following a 75 mg oral dose, peak plasma concentrations averaged 160 ng/mL in 2 to 3 hours.</p> <p>Following a 45 mg IM dose, peak plasma concentrations averaged 140 ng/mL within 60 minutes.</p> <p>Plasma concentrations in surgical patients (5 to 10 minutes after IV injection) may be between 200 – 1000 ng/mL.</p>

Changes effective:
March 1, 2006

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
9400SP	Drugs of Abuse - Medical Professionals, Serum/Plasma (Forensic) <ul style="list-style-type: none"> • Pentazocine 	<p>Following a 75 mg oral dose, peak plasma concentrations averaged 160 ng/mL in 2 to 3 hours.</p> <p>Following a 45 mg IM dose, peak plasma concentrations averaged 140 ng/mL within 60 minutes.</p> <p>Plasma concentrations in surgical patients (5 to 10 minutes after IV injection) may be between 200 – 1000 ng/mL.</p>
9179B	Fluoxetine and Metabolite Screen, Blood <ul style="list-style-type: none"> • Fluoxetine • Norfluoxetine 	<p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4-8 hours after dosing ranges from 91 - 302 ng/mL serum.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4-8 hours after dosing ranges from 72 - 258 ng/mL serum.</p>
9179SP	Fluoxetine and Metabolite Screen, Serum/Plasma <ul style="list-style-type: none"> • Fluoxetine • Norfluoxetine 	<p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4-8 hours after dosing ranges from 91 - 302 ng/mL serum.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4-8 hours after dosing ranges from 72 - 258 ng/mL serum.</p>
5524B	Fluoxetine and Metabolite Confirmation, Blood <ul style="list-style-type: none"> • Fluoxetine • Norfluoxetine 	<p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4-8 hours after dosing ranges from 91 - 302 ng/mL serum.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4-8 hours after dosing ranges from 72 - 258 ng/mL serum.</p>
5524SP	Fluoxetine and Metabolite Confirmation, Serum/Plasma <ul style="list-style-type: none"> • Fluoxetine • Norfluoxetine 	<p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4-8 hours after dosing ranges from 91 - 302 ng/mL serum.</p> <p>Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4-8 hours after dosing ranges from 72 - 258 ng/mL serum.</p>

Changes effective:
March 1, 2006

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
8682B	Fluphenazine, Blood <ul style="list-style-type: none"> Fluphenazine 	Steady-state antipsychotic levels following intramuscular decanoate ester dosing ever 1 to 2 weeks: 0.9 – 4.0 ng/mL at a dose of 12.5mg, 5 – 7 ng/mL at 25 mg, 5 - 17 ng/mL at 50 mg. Effective steady -state antipsychotic plasma levels with oral dosing: 0.1 – 3.0 ng/mL.
8682SP	Fluphenazine, Serum/Plasma <ul style="list-style-type: none"> Fluphenazine 	Steady-state antipsychotic levels following intramuscular decanoate ester dosing ever 1 to 2 weeks: 0.9 – 4.0 ng/mL at a dose of 12.5mg, 5 – 7 ng/mL at 25 mg, 5 - 17 ng/mL at 50 mg. Effective steady -state antipsychotic plasma levels with oral dosing: 0.1 – 3.0 ng/mL.
2150B	Gallium, Blood <ul style="list-style-type: none"> Gallium 	Mean blood concentrations in an unexposed population Was reported as 0.05 +/- 0.02 mcg/dL.
2150R	Gallium, RBC <ul style="list-style-type: none"> Gallium 	Mean blood concentrations in an unexposed population Was reported as 0.05 +/- 0.02 mcg/dL.
2150SP	Gallium, Serum/Plasma <ul style="list-style-type: none"> Gallium 	Mean blood concentrations in an unexposed population Was reported as 0.05 +/- 0.02 mcg/dL.
2150U	Gallium, Urine <ul style="list-style-type: none"> Gallium 	Usually less than 0.5 mcg/L.
5791B	GC Confirmation for Medical Professional Abuse, Blood <ul style="list-style-type: none"> Pentazocine 	Following a 75 mg oral dose, peak plasma concentrations averaged 160 ng/mL in 2 to 3 hours. Following a 45 mg IM dose, peak plasma concentrations averaged 140 ng/mL within 60 minutes. Plasma concentrations in surgical patients (5 to 10 minutes after IV injection) may be between 200 – 1000 ng/mL.

Changes effective:
March 1, 2006

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
5791SP	GC Confirmation for Medical Professional Abuse, Serum/Plasma <ul style="list-style-type: none"> • Pentazocine 	<p>Following a 75 mg oral dose, peak plasma concentrations averaged 160 ng/mL in 2 to 3 hours.</p> <p>Following a 45 mg IM dose, peak plasma concentrations averaged 140 ng/mL within 60 minutes.</p> <p>Plasma concentrations in surgical patients (5 to 10 minutes after IV injection) may be between 200 – 1000 ng/mL.</p>
3233B	GC Screen for Medical Professional Abuse, Blood (Forensic) <ul style="list-style-type: none"> • Pentazocine 	<p>Following a 75 mg oral dose, peak plasma concentrations averaged 160 ng/mL in 2 to 3 hours.</p> <p>Following a 45 mg IM dose, peak plasma concentrations averaged 140 ng/mL within 60 minutes.</p> <p>Plasma concentrations in surgical patients (5 to 10 minutes after IV injection) may be between 200 – 1000 ng/mL.</p>
3233SP	GC Screen for Medical Professional Abuse, Serum/Plasma (Forensic) <ul style="list-style-type: none"> • Pentazocine 	<p>Following a 75 mg oral dose, peak plasma concentrations averaged 160 ng/mL in 2 to 3 hours.</p> <p>Following a 45 mg IM dose, peak plasma concentrations averaged 140 ng/mL within 60 minutes.</p> <p>Plasma concentrations in surgical patients (5 to 10 minutes after IV injection) may be between 200 – 1000 ng/mL.</p>
5790B	GC Confirmation for Medical Professional Abuse, Blood <ul style="list-style-type: none"> • Pentazocine 	<p>Following a 75 mg oral dose, peak plasma concentrations averaged 160 ng/mL in 2 to 3 hours.</p> <p>Following a 45 mg IM dose, peak plasma concentrations averaged 140 ng/mL within 60 minutes.</p> <p>Plasma concentrations in surgical patients (5 to 10 minutes after IV injection) may be between 200 – 1000 ng/mL.</p>

Changes effective:
March 1, 2006

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
5790SP	GC Confirmation for Medical Professional Abuse, Serum/Plasma <ul style="list-style-type: none"> Pentazocine 	<p>Following a 75 mg oral dose, peak plasma concentrations averaged 160 ng/mL in 2 to 3 hours.</p> <p>Following a 45 mg IM dose, peak plasma concentrations averaged 140 ng/mL within 60 minutes.</p> <p>Plasma concentrations in surgical patients (5 to 10 minutes after IV injection) may be between 200 – 1000 ng/mL.</p>
9317SP	Lidocaine and Metabolite (MEGX) Screen, Serum/Plasma <ul style="list-style-type: none"> Monoethylglycinexylidide 	<p>Following a Lidocaine I.V. infusion at rates varying between 20 and 50 mcg/min/kg, steady-state MEGX serum concentrations range from 0.2 – 5.2 mcg/mL.</p>
5613B	Lidocaine and Metabolite (MEGX) Confirmation, Blood <ul style="list-style-type: none"> Monoethylglycinexylidide 	<p>Following a Lidocaine I.V. infusion at rates varying between 20 and 50 mcg/min/kg, steady-state MEGX serum concentrations range from 0.2 – 5.2 mcg/mL.</p>
5613SP	Lidocaine and Metabolite (MEGX) Confirmation, Serum/Plasma <ul style="list-style-type: none"> Monoethylglycinexylidide 	<p>Following a Lidocaine I.V. infusion at rates varying between 20 and 50 mcg/min/kg, steady-state MEGX serum concentrations range from 0.2 – 5.2 mcg/mL.</p>
3400B	Pentazocine, Blood <ul style="list-style-type: none"> Pentazocine 	<p>Following a 75 mg oral dose, peak plasma concentrations averaged 160 ng/mL in 2 to 3 hours.</p> <p>Following a 45 mg IM dose, peak plasma concentrations averaged 140 ng/mL within 60 minutes.</p> <p>Plasma concentrations in surgical patients (5 to 10 minutes after IV injection) may be between 200 – 1000 ng/mL.</p>
3400SP	Pentazocine, Serum/Plasma <ul style="list-style-type: none"> Pentazocine 	<p>Following a 75 mg oral dose, peak plasma concentrations averaged 160 ng/mL in 2 to 3 hours.</p> <p>Following a 45 mg IM dose, peak plasma concentrations averaged 140 ng/mL within 60 minutes.</p> <p>Plasma concentrations in surgical patients (5 to 10 minutes after IV injection) may be between 200 – 1000 ng/mL.</p>

Changes effective:
March 1, 2006

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
8723B	Pentazocine, Blood <ul style="list-style-type: none">Pentazocine	Following a 75 mg oral dose, peak plasma concentrations averaged 160 ng/mL in 2 to 3 hours. Following a 45 mg IM dose, peak plasma concentrations averaged 140 ng/mL within 60 minutes. Plasma concentrations in surgical patients (5 to 10 minutes after IV injection) may be between 200 – 1000 ng/mL.
9441B	Pentazocine Screen, Blood <ul style="list-style-type: none">Pentazocine	Following a 75 mg oral dose, peak plasma concentrations averaged 160 ng/mL in 2 to 3 hours. Following a 45 mg IM dose, peak plasma concentrations averaged 140 ng/mL within 60 minutes. Plasma concentrations in surgical patients (5 to 10 minutes after IV injection) may be between 200 – 1000 ng/mL.
9441SP	Pentazocine Screen, Serum/Plasma <ul style="list-style-type: none">Pentazocine	Following a 75 mg oral dose, peak plasma concentrations averaged 160 ng/mL in 2 to 3 hours. Following a 45 mg IM dose, peak plasma concentrations averaged 140 ng/mL within 60 minutes. Plasma concentrations in surgical patients (5 to 10 minutes after IV injection) may be between 200 – 1000 ng/mL.
5618B	Pentazocine Confirmation, Blood <ul style="list-style-type: none">Pentazocine	Following a 75 mg oral dose, peak plasma concentrations averaged 160 ng/mL in 2 to 3 hours. Following a 45 mg IM dose, peak plasma concentrations averaged 140 ng/mL within 60 minutes. Plasma concentrations in surgical patients (5 to 10 minutes after IV injection) may be between 200 – 1000 ng/mL.

Changes effective:
March 1, 2006

National Medical Services
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslab.com

REFERENCE COMMENT CHANGES – CATEGORY III

Test Code	Test Name	New Reference Comment
5618SP	Pentazocine Confirmation, Serum/Plasma <ul style="list-style-type: none">Pentazocine	Following a 75 mg oral dose, peak plasma concentrations averaged 160 ng/mL in 2 to 3 hours. Following a 45 mg IM dose, peak plasma concentrations averaged 140 ng/mL within 60 minutes. Plasma concentrations in surgical patients (5 to 10 minutes after IV injection) may be between 200 – 1000 ng/mL.
5545SP	Phenothiazines Confirmation, Serum/Plasma <ul style="list-style-type: none">Fluphenazine Overdose	Steady-state antipsychotic levels following intramuscular decanoate ester dosing ever 1 to 2 weeks: 0.9 – 4.0 ng/mL at a dose of 12.5mg, 5 – 7 ng/mL at 25 mg, 5 - 17 ng/mL at 50 mg. Effective steady -state antipsychotic plasma levels with oral dosing: 0.1 – 3.0 ng/mL.
9420SP	Phenothiazines Screen, Serum/Plasma <ul style="list-style-type: none">Fluphenazine Overdose	Steady-state antipsychotic levels following intramuscular decanoate ester dosing ever 1 to 2 weeks: 0.9 – 4.0 ng/mL at a dose of 12.5mg, 5 – 7 ng/mL at 25 mg, 5 - 17 ng/mL at 50 mg. Effective steady -state antipsychotic plasma levels with oral dosing: 0.1 – 3.0 ng/mL.